MGRC aims to make the treatment available to patients in South-East Asia for a fraction of that cost

MALAYSIAN Genomics Resource Centre Bhd (MGRC) is aiming to make its chimeric antigen receptor (CAR) T-Cell treatments available in the country for not more than RM200,000, which is a fraction of the treatment prices in Europe and the US.